16:04 , May 4, 2018 |  BC Week In Review  |  Financial News

Ex-Synageva team planning Kiniksa IPO

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) filed on April 27 to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and Wedbush PacGrow. Kiniksa Chairman and CEO Sanj...
22:02 , Apr 28, 2018 |  BC Extra  |  Financial News

Ex-Synageva team planning Kiniksa IPO

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and Wedbush PacGrow. Kiniksa Chairman and CEO Sanj Patel, President and...
19:27 , May 4, 2017 |  BC Innovations  |  Translation in Brief

A window to IBD

An academia-industry collaboration has identified the cytokine oncostatin M (OSM) as possibly the first biomarker for predicting whether a patient with inflammatory bowel disease (IBD) will respond to anti-tumor necrosis factor α (TNFα) therapy. In a...
08:00 , Jan 21, 2010 |  BC Innovations  |  Targets & Mechanisms

Oncostatin's LIFR sentence

A key challenge in developing osteoporosis therapies that actually promote bone growth-most marketed drugs stop bone loss-is uncoupling the tightly related processes of bone formation and resorption. Now, a group of Australian researchers has found...